Literature DB >> 29174181

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.

David Miles1, David Cameron2, Magalie Hilton3, Josep Garcia4, Joyce O'Shaughnessy5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29174181     DOI： 10.1016/j.ejca.2017.10.018

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  7 in total

1.  Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy.

Authors:  Shogo Nakamoto; Junichiro Watanabe; Shoichiro Ohtani; Satoshi Morita; Masahiko Ikeda
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.

Authors:  Yutaka Yamamoto; Hiroyasu Yamashiro; Andreas Schneeweiss; Volkmar Müller; Oleg Gluz; Peter Klare; Bahriye Aktas; Dank Magdolna; László Büdi; Béla Pikó; László Mangel; Masakazu Toi; Satoshi Morita; Shinji Ohno
Journal:  Breast Cancer       Date:  2022-09-03       Impact factor: 3.307

3.  Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis.

Authors:  Hui Chen; Minglin Liang; Jie Min
Journal:  Balkan Med J       Date:  2021-01       Impact factor: 2.021

4.  Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

Authors:  Sherko Kümmel; Christian Jackisch; Volkmar Müller; Andreas Schneeweiss; Sandra Klawitter; Michael P Lux
Journal:  Cancer Manag Res       Date:  2018-11-08       Impact factor: 3.989

5.  Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation.

Authors:  Alice Clément-Zhao; Marie-Laure Tanguy; Paul Cottu; Brigitte De La Lande; Patrick Bontemps; Claire Lemanski; Pierre Baumann; Alexia Savignoni; Christelle Levy; Karine Peignaux; Agnès Reynaud-Bougnoux; Aline Gobillion; Youlia Kirova
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.240

6.  Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.

Authors:  Yutaka Yamamoto; Hiroyasu Yamashiro; Uhi Toh; Naoto Kondo; Rikiya Nakamura; Masahiro Kashiwaba; Masato Takahashi; Koichiro Tsugawa; Takashi Ishikawa; Takahiro Nakayama; Shoichiro Ohtani; Toshimi Takano; Tomomi Fujisawa; Tatsuya Toyama; Hidetoshi Kawaguchi; Kojiro Mashino; Yuichi Tanino; Satoshi Morita; Masakazu Toi; Shinji Ohno
Journal:  Breast Cancer       Date:  2020-07-26       Impact factor: 4.239

7.  Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.

Authors:  Shogo Nakamoto; Masahiko Ikeda; Shinichiro Kubo; Mari Yamamoto; Tetsumasa Yamashita; Akifumi Notsu
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.